379 related articles for article (PubMed ID: 28685382)
1. Safety and Efficacy of Transarterial Radioembolisation in Patients with Intermediate or Advanced Stage Hepatocellular Carcinoma Refractory to Chemoembolisation.
Klompenhouwer EG; Dresen RC; Verslype C; Laenen A; De Hertogh G; Deroose CM; Bonne L; Vandevaveye V; Maleux G
Cardiovasc Intervent Radiol; 2017 Dec; 40(12):1882-1890. PubMed ID: 28685382
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization.
Hardy-Abeloos C; Lazarev S; Ru M; Kim E; Fischman A; Moshier E; Rosenzweig K; Buckstein M
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):968-976. PubMed ID: 31536781
[TBL] [Abstract][Full Text] [Related]
3. Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis.
Lobo L; Yakoub D; Picado O; Ripat C; Pendola F; Sharma R; ElTawil R; Kwon D; Venkat S; Portelance L; Yechieli R
Cardiovasc Intervent Radiol; 2016 Nov; 39(11):1580-1588. PubMed ID: 27586657
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
[TBL] [Abstract][Full Text] [Related]
5. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
Wang EA; Stein JP; Bellavia RJ; Broadwell SR
Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma.
Moreno-Luna LE; Yang JD; Sanchez W; Paz-Fumagalli R; Harnois DM; Mettler TA; Gansen DN; de Groen PC; Lazaridis KN; Narayanan Menon KV; Larusso NF; Alberts SR; Gores GJ; Fleming CJ; Slettedahl SW; Harmsen WS; Therneau TM; Wiseman GA; Andrews JC; Roberts LR
Cardiovasc Intervent Radiol; 2013 Jun; 36(3):714-23. PubMed ID: 23093355
[TBL] [Abstract][Full Text] [Related]
7. Transarterial Radioembolization Following Chemoembolization for Unresectable Hepatocellular Carcinoma: Response Based on Apparent Diffusion Coefficient Change is an Independent Predictor for Survival.
Klompenhouwer EG; Dresen RC; Verslype C; Laenen A; Bonne L; Vandecaveye V; Maleux G
Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1716-1726. PubMed ID: 29872894
[TBL] [Abstract][Full Text] [Related]
8. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model.
Do Minh D; Chapiro J; Gorodetski B; Huang Q; Liu C; Smolka S; Savic LJ; Wainstejn D; Lin M; Schlachter T; Gebauer B; Geschwind JF
Eur Radiol; 2017 Dec; 27(12):4995-5005. PubMed ID: 28677067
[TBL] [Abstract][Full Text] [Related]
9. Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma.
Kirchner T; Marquardt S; Werncke T; Kirstein MM; Brunkhorst T; Wacker F; Vogel A; Rodt T
Abdom Radiol (NY); 2019 Apr; 44(4):1554-1561. PubMed ID: 30311050
[TBL] [Abstract][Full Text] [Related]
10. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.
Kim DY; Han KH
Hepatol Int; 2016 Nov; 10(6):883-892. PubMed ID: 27126821
[TBL] [Abstract][Full Text] [Related]
11. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?
El Fouly A; Ertle J; El Dorry A; Shaker MK; Dechêne A; Abdella H; Mueller S; Barakat E; Lauenstein T; Bockisch A; Gerken G; Schlaak JF
Liver Int; 2015 Feb; 35(2):627-35. PubMed ID: 25040497
[TBL] [Abstract][Full Text] [Related]
12. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization.
Lewandowski RJ; Kulik LM; Riaz A; Senthilnathan S; Mulcahy MF; Ryu RK; Ibrahim SM; Sato KT; Baker T; Miller FH; Omary R; Abecassis M; Salem R
Am J Transplant; 2009 Aug; 9(8):1920-8. PubMed ID: 19552767
[TBL] [Abstract][Full Text] [Related]
13. The position of transarterial chemoembolization with drug-eluting beads and yttrium-90 transarterial radioembolization in patients with hepatocellular carcinoma: Consensus statements from a Delphi-method expert panel in Turkey.
Akarca US; Akhan O; Bilgiç S; Bozkurt MF; Cantaşdemir M; Çermik TF; Çakaloğlu Y; Er Ö; Ilgıt E; Çapa Kaya G; Küçük NÖ; Numan F; Parıldar M; Türkmen C
Diagn Interv Radiol; 2021 Nov; 27(6):732-739. PubMed ID: 34792027
[TBL] [Abstract][Full Text] [Related]
14. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
Trials; 2012 Aug; 13():144. PubMed ID: 22913492
[TBL] [Abstract][Full Text] [Related]
15. Locoregional Therapy Protocols With and Without Radioembolization for Hepatocellular Carcinoma as Bridge to Liver Transplantation.
Zori AG; Ismael MN; Limaye AR; Firpi R; Morelli G; Soldevila-Pico C; Suman A; Vogel JD; Lazarowicz M; Geller BS; Toskich B; Gonzalo DH; Johnson MW; Cabrera R
Am J Clin Oncol; 2020 May; 43(5):325-333. PubMed ID: 32079854
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
Katsanos K; Kitrou P; Spiliopoulos S; Maroulis I; Petsas T; Karnabatidis D
PLoS One; 2017; 12(9):e0184597. PubMed ID: 28934265
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Drug Eluting Bead TACE with Microspheres <150 μm for the Treatment of Hepatocellular Carcinoma.
Sattler T; Bredt C; Surwald S; Rust C; Rieger J; Jakobs T
Anticancer Res; 2018 Feb; 38(2):1025-1032. PubMed ID: 29374736
[TBL] [Abstract][Full Text] [Related]
19. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
[TBL] [Abstract][Full Text] [Related]
20. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V
J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
